<DOC>
	<DOCNO>NCT00775424</DOCNO>
	<brief_summary>A phase Ib partially blind pilot study evaluate safety immunological effect PENNVAX-B without co-administration construct contain DNA encode expression either IL-12 IL-15 . Primary objectives 1 . To determine safety HIV-1 DNA construct ( PENNVAX-B ) . 2 . To determine safety optimal dose IL-12 IL-15 adjuvant construct give PENNVAX-B . Secondary objectives 1 . To compare various vaccine group immunological response several HIV-1 antigen , utilize ELISPOT assay . 2 . To analyze antibody response vaccine antigens time . 3 . To measure CD8 cell proliferative response vaccine antigens time .</brief_summary>
	<brief_title>PENNVAX-B With Without IL-12 IL-15 DNA Vaccine HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>1 . HIV1 infection document licensed ELISA test kit confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , time study entry . 2 . Taking stable HAART regimen ≥3 month time enrollment . 3 . CD4positive lymphocyte count ≥400 cells/µl two occasion within 60 day enrollment , perform certify flow laboratory . 4 . HIV1 &lt; 75 copies/mL two occasion within 60 day enrollment , perform CLIA certify laboratory . 5 . Laboratory value obtain within 30 day prior study entry : 6 . Hemoglobin &gt; 9 g/dL ( female subject ) &gt; 9.5 g/dL ( male subject ) 7 . Absolute neutrophil count &gt; 1000 cells/μL 8 . Platelet count &gt; 75,000/μL 9 . ALT , AST alkaline phosphatase ≥ 2.5 x upper limit normal range 10 . Total bilirubin ≥ 2.5 x upper limit laboratory normal range 11 . Serum creatinine ≥ upper limit normal ( ULN ) . 12 . All woman reproductive potential ( reach menopause undergone hysterectomy , oophorectomy , tubal ligation ) must negative pregnancy test within 30 day initiate studyspecified medication ( ) day 0 ( enrollment ) . 1 . Women reproductive potential ( reach menopause undergone hysterectomy , oophorectomy , tubal ligation ) whose male partner undergone successful vasectomy resultant azoospermia azoospermia reason , eligible without require use contraception . Documentation menopause , sterilization ( hysterectomy , oophorectomy , tubal ligation , vasectomy ) azoospermia patientreported history acceptable . 2 . All subject must participate conception process ( i.e . active attempt become pregnant impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , female study volunteer/male partner must use form contraception receive protocolspecified medication ( ) /vaccinations one month stop vaccination . 13 . Karnofsky performance score ≥ 90 within 30 day prior study entry . 14 . Men woman ≥18 year age less 50 . 15 . Ability willingness subject legal guardian/representative give write informed consent . 1 . Any active past AIDSdefining illness exception minimal ( less 10 lesion ) cutaneous Kaposi 's sarcoma . 2 . Subjects history CD4+ Tcell count ≤200/µl eligible . 3 . Use known immunomodulatory therapy within 4 week prior study entry include limited drug systemic corticosteroid , interferon , interleukin , thalidomide , granulocytemacrophage colonystimulating factor , IV gammaglobulin , human growth hormone . 4 . Any malignancy require systemic local toxic chemotherapy . Local radiation allow . 5 . Pregnancy breastfeed . 6 . Uncontrolled diabetes mellitus ( fast blood glucose &gt; 126 mg/dL random blood glucose level &gt; 200 mg/dL least two occasion within 6 month prior study entry ) . 7 . Major organ transplantation . 8 . Active alcohol substance abuse psychiatric illness , opinion investigator interfere adherence study requirement . 9 . Clinically significant neurological disorder occur within 1 year prior study entry opinion principal investigator would affect subject 's study compliance safety . 10 . Use systemic corticosteroid ≥ 4 week within 3 month prior study entry . 11 . Presence chronic disease opinion investigator might affect subject safety . 12 . History previous vaccination HIV1 vaccine . 13 . History evidence autoimmune disease , include , limited thyroid autoimmune disease idiopathic thrombocytopenic purpura . 14 . Allergies bupivacaine similar anesthetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>IL-12 adjuvant</keyword>
	<keyword>IL-15 adjuvant</keyword>
</DOC>